# 04_QA_REPORT.md

# Quality Assurance Report

---

# Identity

| Field | Value |
|---|---|
| QA Report ID | QA-PP-0208 |
| Population Package | PP-0208 |
| Title | Palliative Systemic Therapy |
| Version | 1.0.0 |
| Review Status | PASS |
| Production Status | GOLD |
| Decision Status | APPROVED / LOCKED |
| Last Updated | 2026-08-09 |

---

# 1. QA Decision

## Final Decision

# PASS — GOLD — READY FOR INTEGRATION

The four-artifact package was produced after the PP-0208 Decision Batch was explicitly approved and locked.

No architecture blocker remains within the locked scope.

---

# 2. Artifact Completeness QA

| Artifact | Required | Present | Result |
|---|---:|---:|---|
| 01_CKO.md | Yes | Yes | PASS |
| 02_KNOWLEDGE_PASSPORT.md | Yes | Yes | PASS |
| 03_PRIMARY_EVIDENCE_PACKAGE.md | Yes | Yes | PASS |
| 04_QA_REPORT.md | Yes | Yes | PASS |
| ZIP package | Yes | Yes | PASS |
| Boundary declaration | Yes | Yes | PASS |
| Knowledge Graph | Yes | Yes | PASS |
| Evidence Matrix | Yes | Yes | PASS |
| Evidence Gaps | Yes | Yes | PASS |
| Revision History | Yes | Yes | PASS |

---

# 3. Layer 1 — Content QA

## 3.1 Single Educational Question

**Result: PASS**

The package answers one clinical educational question:

> What is palliative systemic therapy for gastric cancer, when is it used, what are its goals, and how are systemic-treatment decisions shaped by disease setting, biomarkers, prior treatment, performance status, toxicity, and patient goals?

The package does not attempt to answer every advanced gastric-cancer treatment question.

---

## 3.2 Scope Respect

**Result: PASS**

Core content is limited to systemic-treatment architecture.

The package includes:

- advanced disease setting;
- treatment intent;
- treatment goals;
- treatment-line structure;
- chemotherapy;
- biomarker-directed systemic treatment;
- performance status;
- prior therapy;
- toxicity;
- treatment response/progression;
- supportive/palliative interface.

---

## 3.3 Exclusion Integrity

**Result: PASS**

The package explicitly excludes:

- dosing;
- schedules;
- detailed FLOT;
- detailed biomarker testing;
- NGS;
- variant interpretation;
- drug-specific treatment ownership;
- radiation planning;
- surgery;
- HIPEC;
- RECIST;
- detailed toxicity management;
- detailed palliative-care protocols;
- individualized treatment.

---

## 3.4 Knowledge Block Completeness

**Result: PASS**

The CKO includes independent blocks covering:

- definition;
- clinical setting;
- treatment goals;
- systemic-treatment sequence;
- biomarkers;
- first-line therapy;
- later-line therapy;
- performance status;
- toxicity;
- supportive care;
- palliative care;
- patient questions;
- misconceptions;
- safety boundary;
- key messages.

---

## 3.5 Patient-Facing Completeness

**Result: PASS**

Patient-facing explanations address:

- what palliative means;
- why systemic therapy is used;
- why treatment differs between people;
- why biomarkers matter;
- what happens after progression;
- why treatment may stop;
- difference between palliative care and anticancer treatment;
- difference between supportive care and “no care.”

---

## 3.6 Common Misconceptions

**Result: PASS**

The package explicitly addresses at least the following:

- palliative treatment does not mean giving up;
- palliative treatment is not the same as supportive care;
- palliative treatment is not limited to the final weeks of life;
- the strongest regimen is not always the best;
- progression does not automatically mean no treatment remains;
- biomarkers do not automatically prescribe treatment;
- stopping anticancer therapy does not mean stopping all care;
- palliative care is not synonymous with hospice.

---

## 3.7 Knowledge Graph

**Result: PASS**

The package defines:

- prerequisite PPs;
- related PPs;
- downstream PPs;
- therapy-specific delegation;
- response-assessment delegation;
- palliative/supportive-care delegation.

The graph preserves the hierarchy:

**Advanced disease**

→

**Palliative systemic treatment**

→

**Targeted / immunotherapy / biomarker-specific treatment**

→

**Response / progression**

→

**Subsequent management**

---

# 4. Layer 1 — Boundary QA

## 4.1 Core Ownership

**PASS**

PP-0208 owns systemic-treatment architecture.

## 4.2 Supporting Ownership

**PASS**

Examples and selected evidence are used only to support the architecture.

## 4.3 Explicit Exclusions

**PASS**

Detailed treatment packages are excluded.

## 4.4 Delegated Ownership

**PASS**

Therapy-specific and downstream packages are explicitly identified.

---

# 5. Layer 1 — Adjacent PP Overlap QA

| Adjacent PP | Overlap Risk | Resolution | Result |
|---|---|---|---|
| PP-0191 Biomarker Testing for Targeted Therapy | High | Testing delegated; treatment architecture retained | PASS |
| PP-0192 Biomarker Testing for Immunotherapy | High | Testing delegated; treatment architecture retained | PASS |
| PP-0203 Perioperative Chemotherapy | High | Curative/perioperative setting excluded | PASS |
| PP-0204 FLOT | High | FLOT excluded except contextual distinction | PASS |
| PP-0205 Adjuvant Therapy | Moderate | Postoperative treatment delegated | PASS |
| PP-0206 Neoadjuvant Therapy | Moderate | Preoperative treatment delegated | PASS |
| PP-0207 Chemoradiation | High | Radiation/combined modality delegated | PASS |
| PP-0209 Targeted Therapy | High | Conceptual targeted-treatment role only | PASS |
| PP-0210 HER2-targeted Therapy | High | HER2 used as example; detailed therapy delegated | PASS |
| PP-0211 CLDN18.2-targeted Therapy | High | CLDN18.2 used as example; detailed therapy delegated | PASS |
| PP-0212 Anti-angiogenic Therapy | High | Ramucirumab used as later-line example | PASS |
| PP-0213 Immunotherapy | High | Immunotherapy used as treatment class; detail delegated | PASS |
| PP-0214 ICI | High | ICI role only; detailed package delegated | PASS |
| PP-0215 MSI-H/dMMR | High | Biomarker branch only; detailed treatment delegated | PASS |
| PP-0216 PD-L1 | High | Biomarker branch only; detailed treatment delegated | PASS |
| PP-0217 Response Assessment | Moderate | Conceptual reassessment only | PASS |
| PP-0218 RECIST | High | Formal RECIST excluded | PASS |
| PP-0219 Post-treatment Imaging | Moderate | Imaging methodology excluded | PASS |
| PP-0222 Recurrent Gastric Cancer | High | Systemic-treatment component only | PASS |
| PP-0223 Metastatic Gastric Cancer | High | Systemic-treatment component only | PASS |
| PP-0224/0225 Peritoneal Disease | Moderate | Peritoneal context only | PASS |
| PP-0227 Palliative Care | High | Interface only | PASS |
| PP-0228 Best Supportive Care | High | Interface only | PASS |
| PP-0231 Toxicity/Supportive Care | High | Toxicity principles only | PASS |

---

# 6. Layer 2 — Clinical QA

## 6.1 Guideline Consistency

**PASS**

The systemic-treatment architecture is aligned with the supplied NCCN Gastric Cancer v2.2026 material.

The source contains dedicated sections for:

- unresectable locally advanced/recurrent/metastatic disease;
- first-line therapy;
- second-line and subsequent therapy;
- targeted therapies;
- palliative/best supportive care.

---

## 6.2 NCI Consistency

**PASS**

The package is consistent with the supplied NCI PDQ regarding:

- stage IV/inoperable/recurrent treatment;
- first-line palliative systemic therapy;
- second-line treatment;
- third-line treatment;
- chemotherapy versus supportive care;
- ramucirumab;
- HER2-directed therapy;
- palliative local interventions.

---

## 6.3 Patient-Facing Source Consistency

**PASS**

NCI Treatment of Stomach Cancer and ACS are used for patient-facing concepts.

The package avoids turning patient-facing material into individualized medical advice.

---

## 6.4 ESMO-ASCO Consistency

**PASS**

The package uses ESMO-ASCO as professional context for:

- systemic treatment;
- performance status;
- toxicity;
- treatment benefit;
- multidisciplinary care;
- progressive disease;
- goals-of-care discussions.

---

# 7. Layer 2 — Clinical Claim QA

| Claim Type | Result | QA Note |
|---|---|---|
| Palliative systemic therapy is active treatment | PASS | Supported |
| Advanced/recurrent/metastatic disease may require systemic treatment | PASS | Supported |
| Systemic therapy can improve survival/quality of life | PASS | Guideline/evidence supported |
| Two-drug regimens generally preferred | PASS | NCCN-supported |
| Triplets reserved for selected fit patients | PASS | NCCN-supported |
| Biomarkers influence treatment | PASS | NCCN/NCI-supported |
| HER2 can redirect treatment | PASS | NCCN/NCI-supported |
| PD-L1 can influence immunotherapy | PASS | NCCN-supported |
| CLDN18.2 can redirect treatment | PASS | NCCN/NCI-supported |
| MSI-H/dMMR can influence immunotherapy | PASS | NCCN/NCI-supported |
| Second-line treatment depends on prior therapy and PS | PASS | NCCN-supported |
| Ramucirumab is a later-line option | PASS | NCCN/NCI-supported |
| Ramucirumab should not simply be added first-line | PASS | NCCN/trial-supported |
| Trastuzumab deruxtecan has later-line activity | PASS | NCCN/NCI-supported |
| Trifluridine/tipiracil is a subsequent option | PASS | NCCN/NCI-supported |
| Best supportive care is legitimate care | PASS | NCCN/NCI-supported |
| Palliative care can coexist with active therapy | PASS | Patient/professional source-supported |

---

# 8. Layer 2 — Unsafe Advice QA

## Result: PASS

No individualized regimen is prescribed.

No dose is provided.

No patient-specific treatment decision is made.

No instruction is given to start, stop, or change treatment.

The safety boundary explicitly requires complete clinical context for individual treatment decisions.

---

# 9. Layer 2 — Overclaiming QA

## Result: PASS

The package avoids statements such as:

- “every patient should receive chemotherapy”;
- “every HER2-positive patient must receive trastuzumab”;
- “PD-L1 automatically determines treatment”;
- “palliative treatment always prolongs survival”;
- “progression means no options remain”;
- “supportive care means no treatment.”

Context-dependent language is deliberately used.

---

# 10. Layer 2 — Evidence Limitation QA

## Result: PASS

The package explicitly identifies:

- lack of one universal regimen;
- lack of one universal sequence;
- lack of universal treatment duration;
- lack of universal stopping criteria;
- biomarker dependence;
- patient-selection dependence;
- evolving treatment evidence.

---

# 11. Layer 3 — Educational QA

## 11.1 Plain Language

**PASS**

Technical terms are explained at first use.

## 11.2 Patient-Friendly Tone

**PASS**

The package uses:

- short conceptual paragraphs;
- question-based explanations;
- clear distinctions;
- neutral language;
- explicit misconception correction.

## 11.3 Logical Flow

**PASS**

The learning sequence is:

**What it is**

→

**When it is used**

→

**Goals**

→

**How treatment is selected**

→

**Biomarkers**

→

**First-line**

→

**Later-line**

→

**Progression**

→

**Supportive/palliative integration**

→

**Patient questions**

---

# 12. Layer 3 — Terminology QA

## Result: PASS

Terms such as:

- palliative;
- systemic therapy;
- performance status;
- biomarker;
- HER2;
- PD-L1;
- CLDN18.2;
- MSI-H;
- dMMR;
- supportive care

are introduced in a clinically understandable context.

---

# 13. Layer 4 — Governance QA

## 13.1 Governance Compliance

**PASS**

The package follows:

- CORE_WORKING_RULES v1.7;
- FREEZE GOLD POPULATION PACKAGE SPECIFICATION v1.1;
- approved Discussion Batch template;
- Source-First rule;
- User-Controlled PP Sequence rule;
- Immediate Gold Artifact Production rule.

---

## 13.2 Four-Artifact Structure

**PASS**

Required artifacts:

1. CKO;
2. Knowledge Passport;
3. Primary Evidence Package;
4. QA Report.

All are present.

---

## 13.3 Gold Depth Rule

**PASS**

The package is intentionally substantive and preserves:

- detailed reasoning;
- evidence traceability;
- patient-facing explanation;
- Knowledge Graph detail;
- boundary detail;
- QA detail.

It is not a compact summary.

---

## 13.4 Versioning

**PASS**

Version:

**1.0.0**

Semantic versioning is used.

---

## 13.5 Boundary Declaration

**PASS**

Boundary is explicitly defined using:

- Core;
- Supporting;
- Explicitly Excluded;
- Delegated-to PP.

The same ownership logic is maintained across all four artifacts.

---

## 13.6 Source Traceability

**PASS**

The Evidence Package identifies:

- source;
- evidence role;
- claim;
- interpretation;
- limitation;
- downstream ownership.

---

# 14. Cross-Artifact Consistency QA

| Element | CKO | KP | Evidence Package | QA | Result |
|---|---|---|---|---|---|
| PP ID | PP-0208 | PP-0208 | PP-0208 | PP-0208 | PASS |
| Title | Palliative Systemic Therapy | Same | Same | Same | PASS |
| Scope | Same | Same | Same | Same | PASS |
| Treatment intent | Palliative | Same | Same | Same | PASS |
| First-line architecture | Present | Present | Present | Verified | PASS |
| Later-line architecture | Present | Present | Present | Verified | PASS |
| Biomarker role | Present | Present | Present | Verified | PASS |
| PS/comorbidity/toxicity | Present | Present | Present | Verified | PASS |
| Supportive/palliative interface | Present | Present | Present | Verified | PASS |
| Boundary | Present | Present | Present | Verified | PASS |
| Knowledge Graph | Present | Present | Present | Verified | PASS |
| Evidence limitations | Present | Present | Present | Verified | PASS |
| Safety boundary | Present | Present | Present | Verified | PASS |

---

# 15. Evidence Traceability QA

## Primary Guideline

**NCCN Gastric Cancer v2.2026**

Supports:

- systemic-treatment pathway;
- first-line treatment;
- later-line treatment;
- biomarker-linked therapy;
- PS/toxicity considerations;
- palliative/BSC pathway.

## Primary Evidence Synthesis

**NCI Gastric Cancer Treatment PDQ**

Supports:

- first-line palliative therapy;
- second-line therapy;
- third-line therapy;
- chemotherapy versus BSC;
- selected trial evidence;
- palliative local treatment.

## Patient-Facing Sources

**NCI Treatment of Stomach Cancer**

**American Cancer Society — Stomach Cancer**

Support:

- treatment-category explanations;
- biomarker-treatment context;
- patient-facing framing.

## Professional Source

**ESMO-ASCO Global Curriculum 2023**

Supports:

- systemic-treatment decision context;
- PS;
- toxicity;
- progressive-disease discussions;
- multidisciplinary care.

---

# 16. Evidence Consistency Review

## NCCN vs NCI

**PASS**

No material conflict identified for the locked scope.

NCCN provides the current treatment framework.

NCI provides evidence synthesis and trial summaries.

They are complementary rather than contradictory.

---

## NCCN/NCI vs Patient-Facing Sources

**PASS**

Patient-facing sources are used for explanatory framing.

They do not override the guideline treatment architecture.

---

## ESMO-ASCO vs Gastric-Cancer-Specific Sources

**PASS**

ESMO-ASCO is used as professional contextual support rather than as a gastric-cancer-specific treatment algorithm.

---

# 17. Clinical Safety Boundary QA

## Result: PASS

The package states that:

- it is educational;
- it is not individualized treatment advice;
- treatment decisions require full clinical context;
- biomarkers do not automatically prescribe treatment;
- no single scan or laboratory result should be treated as a treatment order.

---

# 18. Knowledge Graph QA

## Result: PASS

### Upstream

- Staging;
- Treatment Overview;
- Biomarker Testing;
- Perioperative/Adjuvant/Neoadjuvant context;
- Chemoradiation.

### Current PP

**PP-0208 — Palliative Systemic Therapy**

### Downstream

- Targeted Therapy;
- HER2-targeted Therapy;
- CLDN18.2-targeted Therapy;
- Anti-angiogenic Therapy;
- Immunotherapy;
- ICI;
- MSI-H/dMMR;
- PD-L1;
- Response Assessment;
- RECIST;
- Imaging.

### Parallel/supportive branches

- Recurrent Disease;
- Metastatic Disease;
- Peritoneal Disease;
- Palliative Care;
- Best Supportive Care;
- Treatment Toxicity.

The graph is coherent and non-circular.

---

# 19. Duplicate-Content Risk QA

## Result: PASS

### Major risks reviewed

**PP-0191 / PP-0192**

Testing is not reproduced.

**PP-0203–0206**

Curative-intent systemic therapy is not reproduced.

**PP-0207**

Radiation/chemoradiation is not reproduced.

**PP-0209–0216**

Drug-specific therapy is not reproduced in full.

**PP-0217–0219**

Formal response assessment is not reproduced.

**PP-0222/0223**

Disease-state management is not reproduced in full.

**PP-0227/0228**

Palliative/supportive care is not reproduced in full.

**PP-0231**

Detailed toxicity management is not reproduced.

---

# 20. Patient-Safety QA

| Safety Criterion | Result |
|---|---|
| No individualized prescription | PASS |
| No dosing | PASS |
| No treatment-change instruction | PASS |
| No false certainty | PASS |
| Biomarker limitations acknowledged | PASS |
| Treatment-line dependence acknowledged | PASS |
| Toxicity acknowledged | PASS |
| PS/comorbidity acknowledged | PASS |
| Supportive care acknowledged | PASS |
| Patient goals acknowledged | PASS |
| End-of-life distinction handled carefully | PASS |

---

# 21. Gold Depth QA

## Result: PASS

The package preserves the Gold production principle:

- no compacted CKO;
- no abbreviated Knowledge Passport;
- no shallow Evidence Package;
- no minimal QA;
- no collapsed boundary;
- no reduced patient-facing explanation;
- no reduced Knowledge Graph.

The artifact set is designed as a complete governed knowledge product rather than as a summary.

---

# 22. Governance Final Checklist

| Requirement | Result |
|---|---|
| Source-First | PASS |
| Approved PP scope used | PASS |
| Decision Batch locked before production | PASS |
| Gold specification followed | PASS |
| Four artifacts produced | PASS |
| ZIP package produced | PASS |
| Boundary included | PASS |
| Adjacent PP overlap reviewed | PASS |
| Evidence traceability included | PASS |
| Knowledge Graph included | PASS |
| Evidence gaps included | PASS |
| Patient-facing depth preserved | PASS |
| Clinical safety boundary included | PASS |
| QA four layers completed | PASS |
| Versioning included | PASS |
| Ready for integration | PASS |

---

# 23. Final Boundary

## Core

Palliative systemic therapy for unresectable locally advanced, recurrent, and metastatic gastric cancer; treatment goals; first-line and subsequent-line systemic-treatment architecture; chemotherapy; biomarker-directed treatment strategy; HER2; PD-L1; CLDN18.2; MSI-H/dMMR; performance status; comorbidity; toxicity; prior therapy; progression; treatment change; patient goals; integration with palliative and supportive care.

## Supporting

Representative treatment examples; selected trial evidence; ramucirumab; trastuzumab deruxtecan; trifluridine/tipiracil; selected local palliative-treatment interfaces; peritoneal-disease context; clinical-trial context; symptom/nutrition context.

## Explicitly Excluded

Detailed dosing and schedules; FLOT; detailed biomarker testing; NGS; variant interpretation; detailed therapy-specific packages; radiation planning; surgery; lymphadenectomy; HIPEC; RECIST; imaging methodology; detailed toxicity management; detailed palliative-care/BSC protocols; individualized treatment.

## Delegated-to PP

PP-0191; PP-0192; PP-0203–PP-0207; PP-0209–PP-0216; PP-0217–PP-0219; PP-0222–PP-0225; PP-0227; PP-0228; PP-0231 and future therapy-specific PPs in the authoritative Project Coordinator sequence.

---

# 24. Final QA Status

# PASS — GOLD — READY FOR INTEGRATION

---

# 25. Revision History

| Version | Date | Change |
|---|---|---|
| 1.0.0 | 2026-08-09 | Initial Gold QA after approved/locked PP-0208 Decision Batch. |


# 26. QA — Expanded Clinical Reasoning Review

## Result: PASS

The package does not reduce palliative systemic therapy to chemotherapy alone.

It correctly represents the modern treatment architecture as potentially involving:

- chemotherapy;
- targeted therapy;
- immunotherapy;
- biomarker-directed combinations;
- subsequent-line treatment;
- supportive/palliative integration.

---

# 27. QA — Treatment-Intent Distinction

## Result: PASS

The package clearly distinguishes:

### Curative-intent systemic therapy

from

### Palliative systemic therapy.

Perioperative, neoadjuvant, and adjuvant treatment are not duplicated.

The same drug may appear in both settings, but package ownership is determined by clinical intent and setting.

---

# 28. QA — Treatment-Line Distinction

## Result: PASS

The package distinguishes:

- first-line;
- second-line;
- third-line/subsequent therapy.

It explicitly explains why a therapy may have different roles across lines.

This prevents false generalization from one trial or one drug indication.

---

# 29. QA — Biomarker Architecture

## Result: PASS

The package preserves:

**testing**

→

**result**

→

**clinical relevance**

→

**treatment consideration**

It does not collapse this into:

**biomarker**

→

**automatic prescription**.

The boundaries with PP-0191 and PP-0192 are preserved.

---

# 30. QA — HER2 Boundary

## Result: PASS

HER2 is included only to explain its role in systemic-treatment selection.

Detailed HER2-targeted treatment is delegated to PP-0210.

---

# 31. QA — CLDN18.2 Boundary

## Result: PASS

CLDN18.2 is included only to explain its role in selected first-line treatment.

Detailed CLDN18.2-targeted therapy is delegated to PP-0211.

---

# 32. QA — PD-L1 Boundary

## Result: PASS

PD-L1 is included only as a biomarker that can influence selected immunotherapy-containing strategies.

Detailed PD-L1-guided treatment is delegated to PP-0216.

---

# 33. QA — MSI-H/dMMR Boundary

## Result: PASS

MSI-H/dMMR is included as a biomarker-defined treatment branch.

Detailed disease-specific immunotherapy is delegated to PP-0215.

---

# 34. QA — Targeted Therapy Boundary

## Result: PASS

PP-0208 is not a targeted-therapy catalog.

It explains why targeted therapy can become part of palliative systemic treatment and routes detailed content downstream.

---

# 35. QA — Immunotherapy Boundary

## Result: PASS

PP-0208 is not an immunotherapy package.

It explains immunotherapy as a systemic-treatment component in selected settings and routes detailed content downstream.

---

# 36. QA — Anti-Angiogenic Boundary

## Result: PASS

Ramucirumab is included as a treatment-line example.

Detailed anti-angiogenic treatment is delegated to PP-0212.

The package explicitly prevents the misconception that ramucirumab should simply be added to all first-line chemotherapy.

---

# 37. QA — FLOT Boundary

## Result: PASS

FLOT is not taught as a regimen within PP-0208.

It remains owned by PP-0204.

This prevents duplication with perioperative treatment architecture.

---

# 38. QA — Chemoradiation Boundary

## Result: PASS

Chemoradiation is treated only as an interface.

Radiation planning and combined-modality treatment are delegated to PP-0207.

---

# 39. QA — Surgery Boundary

## Result: PASS

Gastrectomy and lymphadenectomy are not reproduced.

Surgical PPs remain authoritative for surgical technique and principles.

---

# 40. QA — Peritoneal Disease Boundary

## Result: PASS

Peritoneal disease is recognized as a relevant advanced-disease context.

Detailed peritoneal management, cytoreductive surgery, and HIPEC are delegated.

---

# 41. QA — Response Assessment Boundary

## Result: PASS

The package includes the conceptual need for reassessment.

It does not reproduce:

- RECIST;
- formal response criteria;
- imaging protocols.

These remain downstream.

---

# 42. QA — Palliative Care Boundary

## Result: PASS

The package correctly distinguishes:

**palliative systemic therapy**

from

**palliative care**.

It also correctly explains that palliative care can coexist with active anticancer therapy.

Detailed palliative-care content remains delegated.

---

# 43. QA — Best Supportive Care Boundary

## Result: PASS

Best supportive care is presented as:

- active clinical care;
- symptom-focused;
- function-focused;
- quality-of-life focused.

It is not described as “no treatment.”

Detailed BSC remains delegated.

---

# 44. QA — Toxicity Boundary

## Result: PASS

The package explains that toxicity affects systemic-treatment selection and continuation.

It does not reproduce:

- grading;
- prophylaxis;
- dose modification;
- toxicity algorithms.

Detailed toxicity/supportive care remains delegated to PP-0231.

---

# 45. QA — Patient-Centeredness

## Result: PASS

The package consistently incorporates:

- patient goals;
- quality of life;
- functional status;
- treatment burden;
- symptom burden;
- shared decision-making.

This is essential for a palliative-treatment package.

---

# 46. QA — “Palliative” Terminology

## Result: PASS

The package avoids equating:

**palliative**

with:

- hopeless;
- futile;
- hospice;
- final days/weeks;
- no active treatment.

This is a critical patient-safety and educational requirement.

---

# 47. QA — Evidence Language

## Result: PASS

The package distinguishes:

- established/guideline-supported;
- context-dependent;
- evidence-supported but not universal;
- evidence gaps.

No universal prescription language is used.

---

# 48. QA — Trial Evidence Use

## Result: PASS

Trials are used to demonstrate clinical principles.

They are not used to construct individualized treatment instructions.

Selected evidence includes:

- chemotherapy versus supportive care;
- RAINFALL;
- RAINBOW;
- DESTINY-Gastric01;
- CLDN18.2-directed therapy evidence.

---

# 49. QA — Patient Questions

## Result: PASS

Questions cover:

- treatment intent;
- biomarker relevance;
- expected benefit;
- toxicity;
- progression;
- later-line options;
- clinical trials;
- palliative care;
- supportive care;
- stopping treatment.

This supports patient-centered retrieval.

---

# 50. QA — Clinical Safety Language

## Result: PASS

The package explicitly states:

> A treatment decision requires review of the complete clinical context.

It does not advise:

- starting treatment;
- stopping treatment;
- switching treatment;
- selecting a regimen.

---

# 51. QA — Evidence-to-Claim Traceability

## Result: PASS

Major claims are mapped to source families.

NCCN is used for current guideline architecture.

NCI PDQ is used for evidence synthesis.

NCI/ACS are used for patient-facing support.

ESMO-ASCO is used for professional context.

---

# 52. QA — Source-Date Awareness

## Result: PASS

The primary disease-specific source is identified as NCCN Gastric Cancer v2.2026 in the project materials.

The supplied NCI PDQ is dated within the project source set.

The package records the production date separately from the publication/update date of individual sources.

---

# 53. QA — No Silent Reconciliation

## Result: PASS

Where different sources serve different purposes, they are not forced into artificial uniformity.

The package treats:

- NCCN as guideline architecture;
- NCI as evidence synthesis;
- NCI/ACS as patient-facing support;
- ESMO-ASCO as professional educational context.

---

# 54. QA — No Unsupported Expansion

## Result: PASS

The package does not add:

- unreferenced drug algorithms;
- numerical universal thresholds;
- individualized treatment rules;
- technical testing protocols;
- detailed toxicity protocols.

---

# 55. QA — Future Update Robustness

## Result: PASS

The package includes explicit update triggers for:

- guideline changes;
- new biomarker-directed therapies;
- new treatment lines;
- new evidence;
- new therapy-specific PPs;
- governance changes.

---

# 56. QA — Repository Readiness

## Result: PASS

The package includes:

- stable PP identity;
- semantic version;
- four governed artifacts;
- evidence provenance;
- Knowledge Graph;
- boundary;
- QA;
- revision history.

---

# 57. QA — Gold Depth Confirmation

## Result: PASS

The package is intentionally maintained at full Gold depth.

No artifact has been compressed into:

- a summary;
- a short reference card;
- a minimal metadata sheet;
- a short evidence list;
- a superficial QA checklist.

The package preserves the established Gold production philosophy across:

- reasoning;
- evidence;
- patient education;
- Knowledge Graph;
- boundaries;
- QA.

---

# 58. Final Cross-Artifact Audit

| Audit Item | CKO | KP | EP | QA | Result |
|---|---|---|---|---|---|
| Scope | ✓ | ✓ | ✓ | ✓ | PASS |
| Treatment intent | ✓ | ✓ | ✓ | ✓ | PASS |
| Treatment-line logic | ✓ | ✓ | ✓ | ✓ | PASS |
| Biomarker logic | ✓ | ✓ | ✓ | ✓ | PASS |
| Performance status | ✓ | ✓ | ✓ | ✓ | PASS |
| Toxicity | ✓ | ✓ | ✓ | ✓ | PASS |
| Patient goals | ✓ | ✓ | ✓ | ✓ | PASS |
| Supportive care | ✓ | ✓ | ✓ | ✓ | PASS |
| Palliative care | ✓ | ✓ | ✓ | ✓ | PASS |
| Knowledge Graph | ✓ | ✓ | ✓ | ✓ | PASS |
| Boundary | ✓ | ✓ | ✓ | ✓ | PASS |
| Evidence gaps | ✓ | ✓ | ✓ | ✓ | PASS |
| Safety boundary | ✓ | ✓ | ✓ | ✓ | PASS |
| Revision history | ✓ | ✓ | ✓ | ✓ | PASS |

---

# 59. QA Conclusion

The PP-0208 artifact set is internally coherent and clinically conservative within the locked scope.

The defining package ownership remains:

> **Palliative systemic-treatment decision architecture for advanced gastric cancer.**

The package does not claim ownership of:

- every advanced gastric-cancer treatment;
- every biomarker;
- every drug;
- every treatment modality;
- every supportive-care intervention.

This is the principal architecture safeguard.

---

# 60. Final QA Status

# PASS — GOLD — READY FOR INTEGRATION
